妇科恶性肿瘤分子影像引导手术:现状如何?
该综述以叙述性方式梳理妇科恶性肿瘤分子影像引导手术的临床与技术现状,指出前哨淋巴结活检是最常见临床应用,受体靶向与隐匿病灶定位亦有前景;术前SPECT/CT与PET/CT可提供手术路线图,术中探测从一维探头发展到二维便携相机与三维自由手成像;结论认为在放射性引导前哨淋巴结活检与SPECT成功应用后,创新正转向混合示踪剂及SPECT/CT、PET/CT等影像融合,机器人手术与增强现实、虚拟现实技术正推动这些技术进入临床。
要点
- 妇科分子影像引导手术最常见的临床应用是前哨淋巴结活检。
- 受体靶向方式与隐匿病灶定位是其他有前景的方法。
- 术前SPECT/CT与PET/CT可为手术规划提供路线图。
核心结论
- 放射性引导前哨淋巴结活检与SPECT成功应用后,创新正转向混合示踪剂及包括SPECT/CT与PET/CT在内的影像融合。
- 机器人手术以及增强现实与虚拟现实技术正推动这些创新技术应用于临床,引导外科医生实现精准、个体化与微创的手术方式。
研究设计与样本
- 本文为叙述性综述,描述相关文献,聚焦分子影像引导手术在妇科的临床应用、作为手术路线图的术前影像以及术中设备。
主要发现
- 妇科最常见的临床应用是前哨淋巴结活检(SNB)。
- 其他有前景的方法包括受体靶向方式与隐匿病灶定位。
- 术前SPECT/CT与PET/CT可为充分的手术规划提供路线图。
- 术中探测方式涵盖一维探头、二维便携相机与三维自由手成像。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aim of this review is to give an overview of the current status of molecular image-guided surgery in gynaecological malignancies, from both clinical and technological points of view. METHODS: A narrative approach was taken to describe the relevant literature, focusing on clinical applications of molecular image-guided surgery in gynaecology, preoperative imaging as surgical roadmap, and intraoperative devices. RESULTS: The most common clinical application in gynaecology is sentinel node biopsy (SNB). Other promising approaches are receptor-target modalities and occult lesion localisation. Preoperative SPECT/CT and PET/CT permit a roadmap for adequate surgical planning. Intraoperative detection modalities span from 1D probes to 2D portable cameras and 3D freehand imaging. CONCLUSION: After successful application of radio-guided SNB and SPECT, innovation is leaning towards hybrid modalities, such as hybrid tracer and fusion of imaging approaches including SPECT/CT and PET/CT. Robotic surgery, as well as augmented reality and virtual reality techniques, is leading to application of these innovative technologies to the clinical setting, guiding surgeons towards a precise, personalised, and minimally invasive approach.
引用
- Pisano G, Wendler T, Valdés Olmos RA, et al. Molecular image-guided surgery in gynaecological cancer: where do we stand? Eur J Nucl Med Mol Imaging. 2024. PMID: 38233609. doi:10.1007/s00259-024-06604-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。